Clinical application of voriconazole in pediatric patients: a systematic review
Authors:
Open Access
- 9 June 2024
- journal article
- review article
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 50 (1) , 1-12
Abstract
The purpose of this study was to review the literature on the clinical use of voriconazole (VRC) in pediatric patients. MEDLINE, Embase, PubMed, Web of Science, and Cochrane Library were searched from January 1, 2000, to August 15, 2023 for relevant clinical studies on VRC use in pediatric patients. Data were collected based on inclusion and exclusion criteria, and a systematic review was performed on recent research related to the use of VRC in pediatric patients. This systematic review included a total of 35 observational studies among which there were 16 studies investigating factors influencing VRC plasma trough concentrations (Ctrough) in pediatric patients, 14 studies exploring VRC maintenance doses required to achieve target range of Ctrough, and 11 studies focusing on population pharmacokinetic (PPK) research of VRC in pediatric patients. Our study found that the Ctrough of VRC were influenced by both genetic and non-genetic factors. The optimal dosing of VRC was correlated with age in pediatric patients, and younger children usually required higher VRC doses to achieve target Ctrough compared to older children. Establishing a PPK model for VRC can assist in achieving more precise individualized dosing in children.Keywords
Funding Information
- Scientific Research Project of Hunan Provincial Health Commission (W20243243)
- Scientific Research Project of Changsha Municipal Health Commission (KJ-B2023042)
- the Natural Science Foundation of Hunan Province (2024JJ8227)
This publication has 59 references indexed in Scilit:
- Therapeutic Drug Monitoring of Voriconazole After Intravenous Administration in Infants and Children With Primary ImmunodeficiencyTherapeutic Drug Monitoring, 2011
- In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3Drug Metabolism and Disposition, 2010
- Voriconazole Pharmacokinetics and Pharmacodynamics in ChildrenClinical Infectious Diseases, 2010
- Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell TransplantationAntimicrobial Agents and Chemotherapy, 2009
- Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric StudiesAntimicrobial Agents and Chemotherapy, 2009
- CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of VoriconazoleThe Journal of Clinical Pharmacology, 2009
- Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2008
- REGULATION OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS IN INFLAMMATIONAnnual Review of Pharmacology and Toxicology, 2006
- Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose AdministrationAntimicrobial Agents and Chemotherapy, 2004
- Regulation of cytochrome p450 by inflammatory mediators: why and how?2001